Aromatase inhibitor therapy in a cystic fibrosis patient with thoracic endometriosis

Main Article Content

Olga T. Filippova *
Heidi E. Godoy
Patrick F. Timmins III
(*) Corresponding Author:
Olga T. Filippova | filippo@mail.amc.edu

Abstract

The thoracic cavity is the number one site for extrapelvic endometriosis, with catamenial pneumothorax as the most common presenting symptom. Its treatment algorithm is similar to the one for pelvic endometriosis, with the goal of inducing a hypoestrogenic state. However, if medical treatment fails, lung resection may be the only option. We present a case of a 44-year-old female with cystic fibrosis and known pelvic endometriosis, who was diagnosed with thoracic endometriosis after presenting with catamenial hemoptysis. After having a recurrence more than four years after a bilateral salpingo-oophorectomy, she was started on aromatase inhibitor (AI) therapy to avoid lung resection. Such therapy with an AI successfully treated recurrent thoracic endometriosis in a patient with cystic fibrosis, i.e. not an ideal candidate for lung resection.

Downloads month by month

Downloads

Download data is not yet available.

Article Details